Serum Lipopolysaccharide-Binding Protein is Associated with Chronic Inflammation and Metabolic Syndrome in Hemodialysis Patients

2018 ◽  
Vol 47 (1-3) ◽  
pp. 28-36 ◽  
Author(s):  
Paik Seong Lim ◽  
Yu-Kang Chang ◽  
Tsai-Kun Wu
Keyword(s):  
Metabolic Syndrome ◽  
Chronic Inflammation ◽  
Inflammatory Markers ◽  
Binding Protein ◽  
Fasting Blood Glucose ◽  
High Sensitivity ◽  
Acute Phase Reactant ◽  
Lipopolysaccharide Binding Protein ◽  
Markers Of Inflammation ◽  
Lipopolysaccharide Binding

Background: In hemodialysis (HD) patients, impaired gut barrier and alteration in microbiota in the gut is thought to increase the risk of bacterial translocation and chronic inflammation. Lipopolysaccharide-binding protein (LBP) is an acute-phase reactant that mediates immune responses triggered by microbial products. Our aim is to investigate the relationship between circulating levels of LBP, and various metabolic and inflammatory markers in HD patients. Besides, we also aim to determine its relationship among ­patients with different body mass index. Patients and Methods: A total of 123 HD patients were stratified into three ­tertiles, according to serum LBP level. The LBP and inflammatory markers were determined using immunoassay methods. A bioimpedance spectroscopy device was used for body composition measurement. Results: The serum levels of the two proinflammatory markers, high-sensitivity C-reactive protein (hsCRP) and interleukin (IL)-6, were significantly higher in patients in the upper tertile when compared with the rest of the tertiles. In HD patients, a significant positive correlation was found between serum LBP levels and CRP, IL-6, soluble CD14 (sCD14), and fasting blood glucose levels. Patients with metabolic syndrome and pre-existing cardiovascular disease had higher LBP levels than those without metabolic syndrome. Besides, obese patients were also associated with higher serum LBP levels. Multivariate regression analyses showed that IL-6 level was the strongest correlate of LBP level, followed by hsCRP level and sCD14. Conclusions: Our study suggested that elevated plasma LBP was associated with metabolic syndrome and obesity. In addition, increased LBP level was correlated positively to markers of inflammation, and sCD14 levels.

scholarly journals Higher Lipopolysaccharide Binding Protein and Chemerin Concentrations Were Associated with Metabolic Syndrome Features in Pediatric Subjects with Abdominal Obesity during a Lifestyle Intervention

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 289
Author(s):  
Amelia Marti ◽  
Isabel Martínez ◽  
Ana Ojeda-Rodríguez ◽  
María Cristina Azcona-Sanjulian
Keyword(s):  
Metabolic Syndrome ◽  
Children And Adolescents ◽  
Lifestyle Intervention ◽  
Abdominal Obesity ◽  
Plasma Levels ◽  
Intervention Program ◽  
Binding Protein ◽  
Controlled Trial ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

Background: Elevated circulating plasma levels of both lipopolysaccharide-binding protein (LBP) and chemerin are reported in patients with obesity, but few studies are available on lifestyle intervention programs. We investigated the association of both LBP and chemerin plasma levels with metabolic syndrome (MetS) outcomes in a lifestyle intervention in children and adolescents with abdominal obesity Methods: Twenty-nine patients enrolled in a randomized controlled trial were selected. The lifestyle intervention with a 2-month intensive phase and a subsequent 10-month follow-up consisted of a moderate calorie-restricted diet, recommendations to increase physical activity levels, and nutritional education. Results: Weight loss was accompanied by a significant reduction in MetS prevalence (−43%; p = 0.009). Chemerin (p = 0.029) and LBP (p = 0.033) plasma levels were significantly reduced at 2 months and 12 months, respectively. At the end of intervention, MetS components were associated with both LBP (p = 0.017) and chemerin (p < 0.001) plasma levels. Conclusions: We describe for the first time a reduction in both LBP and chemerin plasma levels and its association with MetS risk factors after a lifestyle intervention program in children and adolescents with abdominal obesity. Therefore, LBP and chemerin plasma levels could be used as biomarkers for the progression of cardiovascular risk in pediatric populations.

scholarly journals Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but does not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy

2016 ◽  
Vol 1 (1) ◽  
pp. 118 ◽  
Author(s):  
Nicholas Funderburg ◽  
Morgan Boucher ◽  
Abdus Sattar ◽  
Manjusha Kulkarni ◽  
Danielle Labbato ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Immune Activation ◽  
Inflammatory Markers ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Lipopolysaccharide Binding Protein ◽  
Fatty Acid Binding ◽  
Barrier Integrity ◽  
Acid Binding Protein ◽  
Lipopolysaccharide Binding

Introduction: Altered gastrointestinal (GI) barrier integrity and subsequent microbial translocation may contribute to immune activation in HIV infection. We have reported that rosuvastatin improved several markers of immune activation in HIV+ participants, but the effect of statin treatment on markers of GI barrier dysfunction is unknown.Methods: SATURN-HIV is a randomized, double-blind, placebo-controlled trial assessing the effect of rosuvastatin (10mg/daily) on markers of cardiovascular disease, inflammation, and immune activation in ART-treated patients. Gut-barrier integrity was assessed by the surrogate markers intestinal fatty acid binding protein (I-FABP), a marker of enterocyte death, and zonulin-1, a marker of gut epithelial cell function. Levels of lipopolysaccharide binding protein (LBP) were measured as a marker of microbial translocation.Results: Rosuvastatin significantly reduced levels of I-FABP during the treatment period compared to the placebo. There was no effect of rosuvastatin treatment on levels of zonulin or LBP. Baseline levels of LBP were directly related to several markers of immune activation in samples from all participants, including soluble CD163, IP-10, VCAM-1, TNFR-II, and the proportion of CD4+ and CD8+ T cells expressing CD38 and HLA-DR. Many of these relationships, however, were not seen in the statin arm alone at baseline or over time, as inflammatory markers often decreased and LBP levels were unchanged.Conclusions: Forty-eight weeks of rosuvastatin treatment reduced levels of I-FABP, but did not affect levels of zonulin or LBP. The reduction in levels of inflammatory markers that we have reported with rosuvastatin treatment is likely mediated through other mechanisms not related to gut integrity or microbial translocation.SATURN-HIV is registered on clinicaltrials.gov; Identifier: NCT01218802

scholarly journals Lipopolysaccharide-binding protein, neopterin and interferon-gamma as indices of inflammation activity in patients with acute brucellosis

2018 ◽  
Vol 10 (4) ◽  
pp. 96-103
Author(s):  
I. V. Sannikova ◽  
O. V. Mahinja ◽  
N. I. Kovalevich ◽  
N. S. Sarkisjan ◽  
M. V. Titorenko
Keyword(s):  
Binding Protein ◽  
Clinical Manifestations ◽  
Interferon Γ ◽  
Lipopolysaccharide Binding Protein ◽  
Reactive Protein ◽  
Markers Of Inflammation ◽  
Before And After ◽  
Acute Form ◽  
Active Inflammation ◽  
Lipopolysaccharide Binding

Brucellosis is characterized by nonspecific clinical manifestations, the possibility of subclinical flow, the development of relapses and chronic course. Currently, there are nolaboratory criteria to assess the activity of inflammation in brucellosis, the effectiveness of the therapy, predict the outcome of the disease and the risks of recurrence. Available in clinical practice, laboratory tests to assess inflammation, in particular, erythrocyte sedimentation rate, C-reactive protein, leukocyte level, with brucellosis infection are almost not informative. An important role in the development of the cellular immune response against brucella is played by interferon-γ, lipopolysaccharide-binding protein and neopterin. The aim of the study was to determine the level of lipopolysaccharide-binding protein, neopterin and interferon-γ,in the serum of patients with acute form of brucellosis beforeand after antibacterial treatment. When studying the blood of patients with acute brucellosis before and after therapy, the indices of neopterin, lipopolysaccharide-binding protein and interferon-γ were significantly higher than normalvalues. The obtained results testify to the persisting active inflammation and the formation of a chronic brucellosis. Determination of the level of lipopolysaccharide-binding protein, neopterin and interferon-γ in the blood of patients withbrucellosis can be used as markers of inflammation and in monitoring the effectiveness of antibacterial therapy.

Sign in / Sign up

Export Citation Format

Share Document